Humacyte 13D/A Amendment Filed

TL;DR

Humacyte 13D/A filed by Niklason & Dougan - ownership update.

AI Summary

Laura E. Niklason and Brady W. Dougan filed an amendment (No. 9) to their Schedule 13D for Humacyte, Inc. on November 20, 2024. This filing relates to their beneficial ownership of Humacyte's common stock. The filing does not disclose specific new share acquisitions or changes in ownership percentages, but rather updates information as required by SEC regulations.

Why It Matters

This filing indicates ongoing reporting by significant shareholders of Humacyte, Inc., providing transparency on beneficial ownership.

Risk Assessment

Risk Level: low — This is a routine amendment to a Schedule 13D filing, typically for updating information rather than signaling a major event.

Key Players & Entities

• Humacyte, Inc. (company) — Subject Company
• Laura E. Niklason (person) — Filing Person
• Brady W. Dougan (person) — Filing Person
• Alpha Healthcare Acquisition Corp. (company) — Former Company Name

FAQ

Key Financial Figures

• $0.0001 — me of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securiti
• $5.42 — n market at a weighted average price of $5.42 per share for an aggregate sale price o
• $855,000 — n aggregate sale price of approximately $855,000 (excluding commissions). On September
• $5.23 — n market at a weighted average price of $5.23 per share for an aggregate sale price o
• $1,511,000 — n aggregate sale price of approximately $1,511,000 (excluding commissions). On November 1
• $4.44 — n market at a weighted average price of $4.44 per share for an aggregate sale price o
• $3,604,000 — n aggregate sale price of approximately $3,604,000 (excluding commissions). On November 1
• $4.34 — n market at a weighted average price of $4.34 per share for an aggregate sale price o
• $1,854,000 — n aggregate sale price of approximately $1,854,000 (excluding commissions). On November 1
• $8,000 — gregate purchase price of approximately $8,000 (excluding commissions). Dr. Niklason u
• $4.40 — n market at a weighted average price of $4.40 per share for an aggregate sale price o
• $1,149,000 — n aggregate sale price of approximately $1,149,000 (excluding commissions). Mr. Dougan us

Filing Documents

• humaschedule13d_a9.htm (SC 13D/A) — 91KB
• 0001818382-24-000210.txt ( ) — 93KB

Source and Amount of Funds or Other Consideration

Item 3. Source and Amount of Funds or Other Consideration

of the Schedule 13D is hereby amended to be supplemented by the following

Item 3 of the Schedule 13D is hereby amended to be supplemented by the following On September 9, 2024 Ayabudge LLC (" Ayabudge ") sold 157,704 shares of Common Stock in the open market at a weighted average price of $5.42 per share for an aggregate sale price of approximately $855,000 (excluding commissions). On September 10, 2024 Ayabudge sold 288,674 shares of Common Stock in the open market at a weighted average price of $5.23 per share for an aggregate sale price of approximately $1,511,000 (excluding commissions). On November 18, 2024 Ayabudge sold 811,172 shares of Common Stock in the open market at a weighted average price of $4.44 per share for an aggregate sale price of approximately $3,604,000 (excluding commissions). On November 19, 2024 Ayabudge sold 427,459 shares of Common Stock in the open market at a weighted average price of $4.34 per share for an aggregate sale price of approximately $1,854,000 (excluding commissions). On November 19, 2024 Dr. Niklason purchased 1,797 shares of Common Stock in the open market at a weighted average price of $4.44 per share for an aggregate purchase price of approximately $8,000 (excluding commissions). Dr. Niklason used personal funds for such acquisition. On November 20, 2024 Ayabudge sold 261,369 shares of Common Stock in the open market at a weighted average price of $4.40 per share for an aggregate sale price of approximately $1,149,000 (excluding commissions). Mr. Dougan used the proceeds of the sales by Ayabudge to pay down leverage while providing a mechanism for the purchasers to acquire shares at a time that the Issuer was not conducting a financing transaction. Dr. Niklason is treated as indirectly beneficially owning the shares of Common Stock sold. However, no shares of Common Stock directly owned by Dr. Niklason were sold in these transactions.

Interest in Securities of the Issuer

Item 5. Interest in Securities of the Issuer

of the Schedule 13D is hereby amended and restated in full as follows

Item 5 of the Schedule 13D is hereby amended and restated in full as follows (a)-(b) Number of shares of Common Stock beneficially owned Laura E. Niklason, M.D., Ph.D. 6,007,745 shares Brady W. Dougan 6,007,745 shares CUSIP No. 44486Q 103 Page 5 of 6 Pages Percent of class Laura E. Niklason, M.D., Ph.D. 4.6% Brady W. Dougan 4.6% The percentage ownership was calculated based upon 128,668,484 shares of the Issuer's Common Stock outstanding, which includes 125,859,496 shares of the Issuer's Common Stock outstanding as of November 1, 2024, as reported in the Form 10-Q filed with the SEC on November 8, 2024 and 2,808,988 shares issued on November 15, 2024 in the Equity Offering, as reported in the Prospectus Supplement filed with the SEC on November 14, 2024. Number of shares as to which such person has (i) Sole power to vote or to direct the vote Laura E. Niklason, M.D., Ph.D. 0 shares Brady W. Dougan 0 shares (ii) Shared power to vote or to direct the vote Laura E. Niklason, M.D., Ph.D. 6,007,745 shares Brady W. Dougan 6,007,745 shares (iii) Sole power to dispose or to direct the disposition of Laura E. Niklason, M.D., Ph.D. 0 shares Brady W. Dougan 0 shares (iv) Shared power to dispose or to direct the disposition of Laura E. Niklason, M.D., Ph.D. 6,007,745 shares Brady W. Dougan 6,007,745 shares (c) Except as reported in this Schedule 13D, none of the Reporting Persons has effected any transactions in the Common Stock during the past sixty (60) days. (d) Not applicable. (e) As a result of the transactions described herein, on November 19, 2024 each of the Reporting Persons ceased to be the beneficial owner of more than 5% of the Common Stock. The filing of this Amendment No. 9 represents the final amendment to the Schedule 13D and constitutes an exit filing for the Reporting Persons. CUSIP No. 44486Q 103 Page 6 of 6 Pages SIGNATURE After reasonable inquiry and to the best of each of the undersigned's knowledge and be

View Full Filing

View this SC 13D/A filing on SEC EDGAR